SCHEDULE: T. Rowe Price Reports 6% Stake in Celldex Therapeutics

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Celldex Therapeutics' common stock as of June 30, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating their beneficial ownership of Celldex Therapeutics' common stock.
• As of June 30, 2026, T. Rowe Price Associates, Inc. beneficially owned 4,686,187 shares, representing 6.0% of the class of securities.
• The filing specifies sole voting power for 4,683,226 shares and sole dispositive power for 4,686,187 shares.
• T. Rowe Price Associates, Inc. certifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without indicating new strategic investment or divestment.

Positives

• T. Rowe Price Associates, Inc., a significant institutional investor, holds a notable stake (6.0%) in Celldex Therapeutics, which can be seen as a vote of confidence in the company's long-term prospects.
• The filing indicates T. Rowe Price has sole voting and dispositive power over its shares, suggesting clear control and intent regarding its investment.

Negatives

• The filing does not provide specific details on the timing or nature of the acquisition of these shares, making it difficult to assess recent investment activity.
• The filing explicitly denies beneficial ownership for the purpose of changing or influencing control, which might temper expectations of activist involvement.

Risks

• As with any investment, the value of Celldex Therapeutics' common stock is subject to market fluctuations and company-specific performance risks.
• Changes in beneficial ownership by large institutional investors can sometimes precede significant corporate actions, the outcome of which is uncertain.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Celldex Therapeutics. It is a disclosure of beneficial ownership by T. Rowe Price Associates, Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• T. Rowe Price Associates, Inc. certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are common in the biotechnology sector, reflecting active portfolio management by investment firms. The 6.0% stake by T. Rowe Price indicates a significant, but not controlling, position in Celldex Therapeutics.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may influence market perception and trading activity.
• Management: The filing reinforces that T. Rowe Price is not seeking to influence control, allowing management to proceed with existing strategies.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold and manage its investment in Celldex Therapeutics' common stock.
• Celldex Therapeutics will continue its operations and strategic initiatives as previously disclosed.

Key Dates

Keywords

Celldex Therapeutics, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management